Providing stock analysis for investors of the Canadian junior markets
PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical trial stage for a reformulated drug. The firms subsidiary Sairiyo Therapeutics, a joint venture with PharmaTher (CSE: PHRM), has submitted an application for a Phase 1 clinical trial of PD-001.
Read more
PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its ketamine combination formulation, Ketabet. The
Read more
PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will
Read more
PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th. Maxim Group initiated coverage on
Read more
PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the development of Ketabet. The company
Read more
PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The arrangement will see the two
Read more
PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA for orphan drug designation as
Read more
PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an investigational new drug. The approval
Read more
PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the filing of a provisional patent
Read more
PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company this morning announced the submittal
Read more